Literature DB >> 27013100

ATRA transcriptionally induces nSMase2 through CBP/p300-mediated histone acetylation.

Christopher J Clarke1, Achraf A Shamseddine1, Joseph J Jacob1, Gabrielle Khalife1, Tara A Burns2, Yusuf A Hannun3.   

Abstract

Neutral sphingomyelinase-2 (nSMase2) is a key ceramide-producing enzyme in cellular stress responses. While many posttranslational regulators of nSMase2 are known, emerging evidence suggests a more protracted regulation of nSMase2 at the transcriptional level. Previously, we reported that nSMase2 is induced by all-trans retinoic acid (ATRA) in MCF7 cells and implicated nSMase2 in ATRA-induced growth arrest. Here, we further investigated how ATRA regulates nSMase2. We find that ATRA regulates nSMase2 transcriptionally through the retinoic acid receptor-α, but this is independent of previously identified transcriptional regulators of nSMase2 (Sp1, Sp3, Runx2) and is not through increased promoter activity. Epigenetically, the nSMase2 gene is not repressively methylated in MCF7 cells. However, inhibition of histone deacetylases (HDACs) with trichostatin A (TSA) induced nSMase2 comparably to ATRA; furthermore, combined ATRA and TSA treatment was not additive, suggesting ATRA regulates nSMase2 through direct modulation of histone acetylation. Confirming this, the histone acetyltransferases CREB-binding protein and p300 were required for ATRA induction of nSMase2. Finally, use of class-specific HDAC inhibitors suggested that HDAC4 and/or HDAC5 are negative regulators of nSMase2 expression. Collectively, these results identify a novel pathway of nSMase2 regulation and suggest that physiological or pharmacological modulation of histone acetylation can directly affect nSMase2 levels.
Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  all-trans retinoic acid; epigenetic; histone acetyltransferase; histone deacetylase; neutral sphingomyelinase-2; nuclear receptors; retinoids; signal transduction; sphingolipids; transcription

Mesh:

Substances:

Year:  2016        PMID: 27013100      PMCID: PMC4847633          DOI: 10.1194/jlr.M067447

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  46 in total

1.  Neutral sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury.

Authors:  Simone Filosto; Sianna Castillo; Aaron Danielson; Lisa Franzi; Elaine Khan; Nick Kenyon; Jerold Last; Kent Pinkerton; Rubin Tuder; Tzipora Goldkorn
Journal:  Am J Respir Cell Mol Biol       Date:  2010-05-06       Impact factor: 6.914

2.  Transcriptional regulation of neutral sphingomyelinase 2 in all-trans retinoic acid-treated human breast cancer cell line, MCF-7.

Authors:  Hiromi Ito; Kouji Tanaka; Kazumi Hagiwara; Misa Kobayashi; Asuka Hoshikawa; Naoki Mizutani; Akira Takagi; Tetsuhito Kojima; Sayaka Sobue; Masatoshi Ichihara; Motoshi Suzuki; Keiko Tamiya-Koizumi; Mitsuhiro Nakamura; Yoshiko Banno; Yoshinori Nozawa; Takashi Murate
Journal:  J Biochem       Date:  2012-04-11       Impact factor: 3.387

3.  CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells.

Authors:  Eric C Dietze; Michelle M Troch; Michelle L Bowie; Lisa Yee; Gregory R Bean; Victoria L Seewaldt
Journal:  Biochem Biophys Res Commun       Date:  2003-03-21       Impact factor: 3.575

4.  A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk.

Authors:  Gaia Bistulfi; Silvia Pozzi; MingQiang Ren; Stefano Rossetti; Nicoletta Sacchi
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

5.  Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.

Authors:  Anita L Sabichi; Hui Xu; Susan Fischer; Changchan Zou; Xiulan Yang; Vernon E Steele; Gary J Kelloff; Reuben Lotan; John L Clifford
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

6.  Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin.

Authors:  Hiromi Ito; Masashi Murakami; Ayako Furuhata; Siqiang Gao; Kayo Yoshida; Sayaka Sobue; Kazumi Hagiwara; Akira Takagi; Tetsuhito Kojima; Motoshi Suzuki; Yoshiko Banno; Kouji Tanaka; Keiko Tamiya-Koizumi; Mamoru Kyogashima; Yoshinori Nozawa; Takashi Murate
Journal:  Biochim Biophys Acta       Date:  2009-08-19

Review 7.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

8.  Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.

Authors:  Françoise Maupas-Schwalm; Aurélie Bedel; Nathalie Augé; Marie-Hélène Grazide; Elodie Mucher; Jean-Claude Thiers; Robert Salvayre; Anne Nègre-Salvayre
Journal:  Cell Signal       Date:  2009-09-06       Impact factor: 4.315

9.  Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells.

Authors:  Christopher J Clarke; J Michael Guthrie; Yusuf A Hannun
Journal:  Mol Pharmacol       Date:  2008-07-24       Impact factor: 4.436

10.  Neutral sphingomyelinase 2 (nSMase2) is a phosphoprotein regulated by calcineurin (PP2B).

Authors:  Simone Filosto; William Fry; Anne A Knowlton; Tzipora Goldkorn
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

View more
  2 in total

Review 1.  Sphingolipids and their metabolism in physiology and disease.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  Nat Rev Mol Cell Biol       Date:  2017-11-22       Impact factor: 94.444

Review 2.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.